ATE548384T1 - Ein die angiogenese inhibierendes chimäres protein und dessen verwendung - Google Patents
Ein die angiogenese inhibierendes chimäres protein und dessen verwendungInfo
- Publication number
- ATE548384T1 ATE548384T1 AT05752254T AT05752254T ATE548384T1 AT E548384 T1 ATE548384 T1 AT E548384T1 AT 05752254 T AT05752254 T AT 05752254T AT 05752254 T AT05752254 T AT 05752254T AT E548384 T1 ATE548384 T1 AT E548384T1
- Authority
- AT
- Austria
- Prior art keywords
- chimeric protein
- inhibiting angiogenesis
- protein inhibiting
- recombinant
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200410044965 | 2004-06-08 | ||
PCT/CN2005/000802 WO2005121176A1 (fr) | 2004-06-08 | 2005-06-08 | Proteine chimerique inhibitrice d'angiogenese et utilisation associee |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE548384T1 true ATE548384T1 (de) | 2012-03-15 |
Family
ID=35503012
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05752254T ATE548384T1 (de) | 2004-06-08 | 2005-06-08 | Ein die angiogenese inhibierendes chimäres protein und dessen verwendung |
Country Status (13)
Country | Link |
---|---|
US (2) | US7750138B2 (de) |
EP (1) | EP1767546B1 (de) |
JP (1) | JP4680997B2 (de) |
KR (1) | KR100897379B1 (de) |
AT (1) | ATE548384T1 (de) |
BR (1) | BRPI0512286B8 (de) |
CA (1) | CA2569108C (de) |
DK (1) | DK1767546T3 (de) |
ES (1) | ES2381014T3 (de) |
PL (1) | PL1767546T3 (de) |
PT (1) | PT1767546E (de) |
RU (1) | RU2355414C2 (de) |
WO (1) | WO2005121176A1 (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2586459T (lt) | 2005-03-25 | 2017-09-25 | Regeneron Pharmaceuticals, Inc. | Vegf antagonisto kompozicijos |
CN100502945C (zh) * | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
US8216575B2 (en) * | 2006-03-31 | 2012-07-10 | Chengdu Kanghong Biotechnologies Co., Ltd. | Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains |
ES2406764T3 (es) | 2006-06-16 | 2013-06-10 | Regeneron Pharmaceuticals, Inc. | Formulaciones que comprenden antagonistas de VEGF para administración intravítrea |
CN101838329A (zh) * | 2009-03-18 | 2010-09-22 | 嘉和生物药业有限公司 | 抗血管新生融合蛋白 |
KR101248912B1 (ko) * | 2009-12-31 | 2013-03-29 | 한양대학교 산학협력단 | 항혈관신생 활성을 가지는 재조합 아데노바이러스 |
KR20180023015A (ko) | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
EP3858405B1 (de) | 2012-06-01 | 2023-04-05 | Novartis AG | Spritze |
JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
AU2012101678B4 (en) | 2012-07-03 | 2013-01-24 | Novartis Ag | Use of device |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
US20160129080A1 (en) | 2013-06-20 | 2016-05-12 | Aaron Osborne | Treatment of polypoidal chroidal vasculopathy |
US20160130321A1 (en) | 2013-06-20 | 2016-05-12 | Gabriela Burian | Use of a vegf antagonist in treating macular edema |
EP3010525A1 (de) | 2013-06-20 | 2016-04-27 | Novartis AG | Verwendung eines vegf-antagonisten bei der behandlung von choroidaler neovaskularisation |
CN105377891A (zh) | 2013-07-11 | 2016-03-02 | 诺华股份有限公司 | Vegf拮抗剂在治疗儿童患者的脉络膜视网膜新生血管和通透性疾病中的应用 |
CA3107182A1 (en) | 2013-07-12 | 2015-01-15 | Iveric Bio, Inc. | Methods for treating or preventing ophthalmological conditions |
BR112016015187A2 (pt) * | 2014-01-25 | 2018-06-05 | Chengdu Kanghong Biotechnologies Co., Ltd | proteína de fusão para inibição da angiogênese ou do crescimento e uso da mesma |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
KR20180012832A (ko) | 2015-06-28 | 2018-02-06 | 올제네시스 바이오테라퓨틱스 아이엔씨. | 혈관신생 억제용 융합 단백질 |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
CA3010056A1 (en) | 2015-12-30 | 2017-07-06 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
WO2017148904A1 (en) | 2016-02-29 | 2017-09-08 | Franz Grus | Predictive markers useful in the treatment of wet age-related macular degeneration |
WO2018224644A1 (en) | 2017-06-08 | 2018-12-13 | Novartis Ag | Injection device and injection solution transferring system |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
CN111032092A (zh) * | 2017-06-30 | 2020-04-17 | 韩国科学技术院 | Vegf-grab蛋白与药物的缀合物及其用途 |
KR102659791B1 (ko) | 2017-07-06 | 2024-04-23 | 리제너론 파마슈티칼스 인코포레이티드 | 당단백질을 만들기 위한 세포 배양 과정 |
EP3790532A1 (de) | 2018-05-10 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | Hochkonzentriertes vegf-rezeptor-fusionsprotein mit formulierungen |
US20220332792A1 (en) * | 2019-09-04 | 2022-10-20 | University Of Massachusetts | Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof |
EP4041312A4 (de) | 2019-10-10 | 2023-12-20 | Kodiak Sciences Inc. | Verfahren zur behandlung einer augenstörung |
WO2021108530A1 (en) * | 2019-11-26 | 2021-06-03 | University Of Massachusetts | Recombinant adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
US20230052782A1 (en) | 2019-12-12 | 2023-02-16 | Novartis Ag | Injection device and injection solution transferring system |
UY39324A (es) | 2020-07-16 | 2022-02-25 | Novartis Ag | Anticuerpos anti-betacelulina, sus fragmentos, moléculas de unión multiespecíficas, casetes de expresión, composiciones y métodos de tratamiento. |
US20230340529A1 (en) * | 2020-09-03 | 2023-10-26 | University Of Massachusetts | Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof |
TW202313095A (zh) | 2021-05-17 | 2023-04-01 | 美商再生元醫藥公司 | 用於治療血管新生眼疾之延長、高劑量vegf拮抗劑方案 |
EP4145456A1 (de) | 2021-09-06 | 2023-03-08 | Bayer AG | Vorhersage einer änderung in zusammenhang mit einer makulaflüssigkeit |
US20230295266A1 (en) | 2022-03-15 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Extended, High Dose VEGF Antagonist Regimens for Treatment of Angiogenic Eye Disorders |
WO2023177691A1 (en) | 2022-03-15 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0694042B1 (de) * | 1993-03-25 | 2004-11-03 | Merck & Co. Inc. | Inhibitor des wachstumsfaktors für gefäss-endothelzellen |
US6020473A (en) | 1995-08-25 | 2000-02-01 | Genentech, Inc. | Nucleic acids encoding variants of vascular endothelial cell growth factor |
US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
ATE293164T1 (de) | 1999-06-08 | 2005-04-15 | Regeneron Pharma | Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften |
US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
EP1696949A4 (de) * | 2003-11-10 | 2008-02-06 | Ghc Res Dev Corp | Vegf-rezeptor-antagonisten |
CN101134777A (zh) * | 2006-08-31 | 2008-03-05 | 苏州思坦维生物技术有限责任公司 | 可拮抗血管内皮细胞生长因子的人源化的免疫球蛋白的制备方法及其组合应用 |
-
2005
- 2005-06-08 EP EP05752254A patent/EP1767546B1/de active Active
- 2005-06-08 JP JP2007526176A patent/JP4680997B2/ja active Active
- 2005-06-08 BR BRPI0512286A patent/BRPI0512286B8/pt active IP Right Grant
- 2005-06-08 PT PT05752254T patent/PT1767546E/pt unknown
- 2005-06-08 RU RU2006146995/15A patent/RU2355414C2/ru active
- 2005-06-08 CA CA2569108A patent/CA2569108C/en active Active
- 2005-06-08 DK DK05752254.2T patent/DK1767546T3/da active
- 2005-06-08 AT AT05752254T patent/ATE548384T1/de active
- 2005-06-08 US US11/628,735 patent/US7750138B2/en active Active
- 2005-06-08 KR KR1020067026641A patent/KR100897379B1/ko active IP Right Grant
- 2005-06-08 WO PCT/CN2005/000802 patent/WO2005121176A1/zh active Application Filing
- 2005-06-08 ES ES05752254T patent/ES2381014T3/es active Active
- 2005-06-08 PL PL05752254T patent/PL1767546T3/pl unknown
-
2010
- 2010-05-04 US US12/773,315 patent/US20100215655A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1767546B1 (de) | 2012-03-07 |
RU2355414C2 (ru) | 2009-05-20 |
CA2569108A1 (en) | 2005-12-22 |
ES2381014T3 (es) | 2012-05-22 |
JP2008503243A (ja) | 2008-02-07 |
RU2006146995A (ru) | 2008-07-20 |
US20080206238A1 (en) | 2008-08-28 |
KR20070029204A (ko) | 2007-03-13 |
EP1767546A4 (de) | 2008-03-19 |
KR100897379B1 (ko) | 2009-05-14 |
DK1767546T3 (da) | 2012-04-23 |
US7750138B2 (en) | 2010-07-06 |
PT1767546E (pt) | 2012-03-20 |
JP4680997B2 (ja) | 2011-05-11 |
PL1767546T3 (pl) | 2012-07-31 |
BRPI0512286B8 (pt) | 2021-05-25 |
BRPI0512286B1 (pt) | 2020-03-24 |
EP1767546A1 (de) | 2007-03-28 |
US20100215655A1 (en) | 2010-08-26 |
WO2005121176A1 (fr) | 2005-12-22 |
CA2569108C (en) | 2012-08-21 |
BRPI0512286A (pt) | 2008-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE548384T1 (de) | Ein die angiogenese inhibierendes chimäres protein und dessen verwendung | |
CY1109998T1 (el) | Ενδυναμωτες υποδοχεων γλουταμινικου | |
SE0301653D0 (sv) | Novel compounds | |
PT1913001E (pt) | (r)-n-metilnaltrexona, processos para a sua síntese e sua utilização farmacêutica | |
ATE420970T1 (de) | Auf il-1-rezeptor beruhende antagonisten sowie herstellungs- und verwendungsverfahren | |
BRPI0506771A (pt) | anticorpo, e, composição farmacêutica | |
HK1113790A1 (en) | Selurampanel | |
SE0301373D0 (sv) | Novel compounds | |
DK1373503T3 (da) | Neurotrofiske faktorer | |
ATE514714T1 (de) | Hutnfr1-selektive antagonisten | |
ATE494368T1 (de) | Polypeptide der gh-61-familie | |
ATE543833T1 (de) | Bmp-7-varianten-zusammensetzungen, verfahren und verwendungen | |
DE50305507D1 (de) | Zusammensetzungen zur herstellung von aminoplasterzeugnissen | |
DE602004013557D1 (de) | FLÜSSIGE FORMULIERUNGEN DES TUMORNEKROSEFRAKTOR-BINDUNGSPROTEINs TBP-1 | |
ATE442382T1 (de) | Ein die mam-domäne enthaltendes protein | |
ATE550351T1 (de) | Vegf-d-mutanten und ihre verwendung | |
ATE327987T1 (de) | Methylthiophencarboxanilide | |
ATE502047T1 (de) | T-helper antigenic determinant (thd) peptide | |
DE602004021922D1 (de) | Induktion der blütenbildung | |
ITMO20020113A1 (it) | Procedimento per la decorazione di elementi d'arrredamento, del tipo di mobili o suppellettili | |
SM200100014B (it) | Composizione naturale per la riduzione del peso corporeo |